Mutation Associated with increased Cancer Risk Therapeutic Indication Somatic Test for metastatic PCa Somatic Test for metastatic PCa Somatic Test for metastatic PCa
Mutation Rate in European descendant (%) Mutation Rate in African descendant (%) Reference
BRCA 2
x
PARPi
4.45% 10.02% 4.23% 9.73% Kamran et al.69 Koga et al. 67
ATM
x
PARPi
7.29% 5.75% 9.86% 3.78% Kamran et al.69 Koga et al. 67
PALB2 x 0.83% 2.16% Koga et al. 67
CHECK2 x PARPi 2.32% 1.08% Koga et al. 67
MSH2 x Checkpoint Inhibitor 1.30% 1.62% Koga et al. 67
MSH6 x Checkpoint Inhibitor 1.76% 1.08% Koga et al. 67
FANCA x PARPi 1.11% 0.00% Koga et al. 67
NBN x PARPi 0.65% 1.08% Koga et al. 67
CDK12 (somatic only)
Checkpoint Inhibitor
5.55% 4.73% 11.27% 7.57% Kamran et al.69 Koga et al. 67